Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ovarian Cancer Market Snapshot: AstraZeneca's Lynparza Poised To Lead In Niche Space

Executive Summary

AstraZeneca's Lynparza, Tesaro's Zejula and Clovis' Rubraca have brought much needed advances to patients with ovarian cancer, but the market is relatively small and the competition intense, while unmet need remains high.

You may also be interested in...



Oncology Market Leaders Maintain Their Upper Hand

Drugs like Ibrance and Lynparza show that in the cancer market, it can be hard for new entrants to catch early standouts. 

Tesaro's On The Right Path With Anti-PD-1 Dostarlimab In Endometrial Cancer

Interview: Tesaro Chief Medical Officer Martin Huber addresses dostarlimab GARNET data and provides an update on integration with GlaxoSmithKline.

Clinical Trials In Review: Big Hits And Misses In 2018

Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124264

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel